Protein Degradation
With 47 new degrader developers and 207 trials initiated in 2022 alone, investment into targeted protein degradation is increasing due to it’s ability to eliminate disease-causing proteins and accessing previously undruggable therapeutics targets.
Our mission is to accelerate the development and approval of first-in-class degraders, and innovate the next-generation of selective, orally bioavailable, and effective protein degraders into the clinic.
Bringing Safe & Effective Targeted Protein Degradation Therapies to Patients Faster
The field of TPD is rapidly expanding beyond just PROTACs and molecular glues and into new mechanisms of degradation such as LYTACs, ATACs, AbTACs, RESTORACs, bioPROTACs, and more.
From exclusive industry-dedicated conferences to curated clinical trial and drug database solutions and all year-round knowledge sharing and problem-solving expert networks, we will bring you clarity in this rapidly developing and competitive field of small molecule R&D.
Stay up to date with scientific advancements, solve shared challenges and exchange experience and best practices with other forward-thinking protein degradation experts to make better decisions and accelerate the targeted delivery of effective protein degradation therapies to patients faster.
Featured Protein Degradation Products
Beacon
Conferences
Intelligence
Searchlight
Protein Degradation Products by Type
Make Faster, Better Drug Development Decisions
Premium Insight and Meaningful Connections for Biopharma
Expert-driven, Life Science Market Intelligence Solutions
Premium Insight, Collaborative Learning & Mission-Focused Connections for Biopharma
CONTACT US
Get in touch
We speak to hundreds of biopharmaceutical experts from industry and academia every day. We would love for you to be one of them. Contact us to discover how our events can accelerate your drug development.
Standard Form - Protein Degradation
"*" indicates required fields